Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that UNLOXCYT® (cosibelimab-ipdl) has received a Category 2A recommended option in the updated National Comprehensive Cancer Network® (NCCN®) guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation. This marks a significant milestone, reflecting the growing body of clinical evidence supporting UNLOXCYT.

Clinical Evidence and Patient Benefits

The evidence submitted to NCCN was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable with a median follow-up of 24.1 months and a median duration of response not yet reached. Importantly, fewer than 1% of patients experienced high-grade immune-mediated adverse reactions, which is crucial for this patient population.

Impact on Patient Access

The NCCN Guidelines play a vital role in helping physicians evaluate appropriate treatment options for patients across different disease settings. This designation ensures that appropriate patients can receive this treatment without unnecessary access barriers, offering a therapy that provides durable responses with a low rate of high-grade adverse reactions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Wanbury Limited (WANBURY) has recently received significant recognition for its safety and employee practices. On October 19, 2026, the company announced that its Tanuku and Patalganga facilities have been awarded for their outstanding achievements. Notably, the Patalganga facility in Maharashtra received the “Certificate of Excellence” from the National Safety Council for safety performance for the third consecutive year. Meanwhile, the Tanuku facility in Andhra Pradesh was named the “Best Employer” by the State Government, recognizing its exemplary employee practices and workplace culture.

Recognition for Safety

The Patalganga facility’s continuous commitment to maintaining high safety standards has been acknowledged by receiving the “Certificate of Excellence” from the National Safety Council for three years in a row. This recognition underscores the facility’s dedication to ensuring a safe working environment for its employees and compliance with stringent safety regulations.

Awards for Employee Practices

The Tanuku facility’s award as the “Best Employer” highlights its efforts in fostering a rewarding and compliant workplace. The recognition emphasizes the company’s commitment to employee welfare and its efforts to create a positive workplace culture. These accolades reflect Wanbury’s ongoing efforts to uphold high environment, health, and safety (EHS) standards while adhering to Good Manufacturing Practice (GMP) norms.

Management Commentary

“Our people and their safety are at the heart of everything we do,” said Mr. Mohan Rayana, Director of Wanbury Limited. “These awards for our Tanuku and Patalganga teams recognize their dedication to a safe, compliant, and rewarding workplace. We will keep raising the bar on employee welfare and safety across all our sites.” This statement from Mr. Rayana highlights the company’s dedication to its workforce and its continuous efforts to improve safety and employee practices.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 42.1% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock sits at 16% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.

Natco Pharma Limited (NSE: NATCOPHARM) announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market by its subsidiary NATCO Pharma USA LLC. This launch, in manufacturing collaboration with Teyro Labs Pvt Ltd, aims to address a critical shortage of the product in the U.S. market. Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. The product had estimated sales of USD 27.8 million in the U.S. for the 12 months ending June 2026, according to industry sales data.

Strategic Collaboration

The collaboration with Teyro Labs Pvt Ltd, based in Chennai, is pivotal for the successful manufacturing and distribution of Carboplatin Injection. This strategic move underscores Natco Pharma’s commitment to expanding its oncology portfolio and addressing unmet medical needs in the U.S. market.

Market Impact

The launch of Carboplatin Injection is expected to significantly impact the oncology treatment landscape in the U.S. Natco Pharma Limited’s focus on limited competition molecules and its robust manufacturing capabilities position it as a key player in targeted therapies. With manufacturing facilities approved by leading regulatory authorities, Natco Pharma continues to cater to over 50 global markets.

As a result, Natco Pharma Limited’s launch of Carboplatin Injection marks a significant milestone in its ongoing efforts to provide essential medications to patients worldwide. For more information, visit www.natcopharma.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Natco Pharma Limited

Natco Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Natco drops 16.9% over three months and trades near its 52-week lows. The PEG of 0.48 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 32.8% reflect exceptional pricing power and operational efficiency. The stock sits at 1% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 14.5% and profits at 25.6% CAGR, with D/E of 0.00. Meanwhile, the stock dips 16.9% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.